DYRK1B and Hepatic steatosis: At the molecular level, we have discovered metabolic pathways by which Dyrk1b induces hepatic steatosis (a) by activating mTORC2 and augmenting DNL and (b) by upregulating Fabp1 and CD36 and increasing FA influx into the liver.